Summary of Study ST001391
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000954. The data can be accessed directly via it's Project DOI: 10.21228/M8CM3N This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST001391 |
| Study Title | Metabolic Response in Patients with Post-Treatment Lyme Disease Symptoms/Syndrome |
| Study Summary | Post-treatment Lyme Disease Symptoms/Syndrome (PTLDS) occurs in approximately 10% of Lyme disease patients following antibiotic treatment. Objective biomarkers or specific clinical symptoms to identify PTLDS patients do not currently exist and the PTLDS classification is based on the report of persistent subjective symptoms for ≥ 6 months following antibiotic treatment for Lyme disease. Untargeted liquid chromatography-mass spectrometry metabolomics was used to define metabolic changes that occurred longitudinally in PTLDS and clinically cured non-PTLDS Lyme patients from two separate cohorts. An elastic net regularization model was applied to define the metabolites that classified PTLDS and non-PTLDS patients at different time points, and the PTLDS defining metabolites were evaluated in two sample cohorts using linear discriminant analysis. This study determined that observable metabolic alterations occur between PTLDS and non-PTLDS patients at multiple time points. These metabolic alterations discriminated between PTLDS and non-PTLDS patients and consisted of metabolites of glycerophospholipid, bile acid and acylcarnitine metabolism. Longitudinal analyses showed distinct patterns in metabolite abundance changes that indicated a greater variability in PTLDS vs non-PTLDS patients. These data provide evidence that an objective metabolite-based measurement can distinguish patients with PTLDS and help understand the underlying biochemistry of PTLDS. |
| Institute | Colorado State University |
| Department | Department of Microbiology, Immunology, and Pathology |
| Laboratory | Belisle |
| Last Name | Belisle |
| First Name | John |
| Address | 200 West Lake, Campus Delivery 0922, Colorado State University, Fort Collins, CO, 80523 |
| john.belisle@colostate.edu | |
| Phone | 9704915384 |
| Submit Date | 2020-05-28 |
| Analysis Type Detail | LC-MS |
| Release Date | 2020-09-21 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Combined analysis:
| Analysis ID | AN002320 |
|---|---|
| Analysis type | MS |
| Chromatography type | Reversed phase |
| Chromatography system | Agilent 6520 |
| Column | Poroshell 120 EC-C8 (100 x 2.1mm,2.5um) |
| MS Type | ESI |
| MS instrument type | QTOF |
| MS instrument name | Agilent 6520 QTOF |
| Ion Mode | POSITIVE |
| Units | counts |
MS:
| MS ID: | MS002162 |
| Analysis ID: | AN002320 |
| Instrument Name: | Agilent 6520 QTOF |
| Instrument Type: | QTOF |
| MS Type: | ESI |
| MS Comments: | LC-MS data were processed with MassHunter Profinder version B.08.00 and Mass Profiler Professional version B.14.9.01 (Agilent Technologies) to identify differentiating molecular features (MFs; metabolites defined by a retention time and accurate mass) between PTLDS and non-PTLDS patients at baseline, post-treatment and one-year follow-up in cohort-one. The biosignature-MFs determined using cohort-one were targeted in patient samples from cohort-two using MassHunter Profinder. |
| Ion Mode: | POSITIVE |
| Capillary Voltage: | 4000 |
| Dry Gas Flow: | 10 l/min |
| Dry Gas Temp: | 310 |
| Fragment Voltage: | 120 |
| Nebulizer: | 45 psi |
| Octpole Voltage: | 750 V |
